Investors bought shares of Boston Scientific Corp. (NYSE:BSX) on weakness during trading on Friday. $65.03 million flowed into the stock on the tick-up and $27.02 million flowed out of the stock on the tick-down, for a money net flow of $38.01 million into the stock. Of all companies tracked, Boston Scientific Corp. had the 29th highest net in-flow for the day. Boston Scientific Corp. traded down ($0.06) for the day and closed at $24.28

BSX has been the subject of several research analyst reports. Goldman Sachs Group Inc. raised their price target on shares of Boston Scientific Corp. from $21.00 to $22.00 in a research note on Friday, April 8th. Needham & Company LLC raised their price target on shares of Boston Scientific Corp. from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, April 27th. Evercore ISI raised their price target on shares of Boston Scientific Corp. from $21.50 to $23.50 and gave the stock a “buy” rating in a research note on Wednesday, April 27th. Benchmark Co. restated a “buy” rating and set a $22.00 price target (up previously from $20.00) on shares of Boston Scientific Corp. in a research note on Wednesday, April 27th. Finally, Zacks Investment Research upgraded shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Tuesday, April 12th. Six investment analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company’s stock. Boston Scientific Corp. currently has a consensus rating of “Buy” and a consensus target price of $24.49.

The company’s market cap is $32.96 billion. The stock’s 50-day moving average is $23.35 and its 200 day moving average is $20.33.

Boston Scientific Corp. (NYSE:BSX) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.27 EPS for the quarter, meeting the consensus estimate of $0.27. The business had revenue of $2.13 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same quarter in the previous year, the firm posted $0.22 earnings per share. The business’s revenue was up 15.4% on a year-over-year basis. On average, equities analysts forecast that Boston Scientific Corp. will post $1.10 EPS for the current fiscal year.

In related news, SVP David A. Pierce sold 2,480 shares of the business’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $24.03, for a total value of $59,594.40. Following the completion of the transaction, the senior vice president now directly owns 28,080 shares in the company, valued at approximately $674,762.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 79,960 shares of the business’s stock in a transaction on Tuesday, May 3rd. The shares were sold at an average price of $21.81, for a total transaction of $1,743,927.60. Following the completion of the transaction, the executive vice president now owns 92,020 shares of the company’s stock, valued at $2,006,956.20. The disclosure for this sale can be found here.

Several institutional investors have recently bought and sold shares of BSX. BlackRock Advisors LLC boosted its position in Boston Scientific Corp. by 9.2% in the fourth quarter. BlackRock Advisors LLC now owns 13,697,020 shares of the company’s stock valued at $252,573,000 after buying an additional 1,155,619 shares in the last quarter. Systematic Financial Management LP boosted its position in Boston Scientific Corp. by 4.8% in the fourth quarter. Systematic Financial Management LP now owns 3,659,104 shares of the company’s stock valued at $67,473,000 after buying an additional 167,539 shares in the last quarter. Wells Fargo & Company MN boosted its position in Boston Scientific Corp. by 8.5% in the fourth quarter. Wells Fargo & Company MN now owns 3,302,731 shares of the company’s stock valued at $60,902,000 after buying an additional 260,006 shares in the last quarter. Morgan Stanley boosted its position in Boston Scientific Corp. by 11.3% in the fourth quarter. Morgan Stanley now owns 1,919,754 shares of the company’s stock valued at $35,401,000 after buying an additional 194,734 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in Boston Scientific Corp. by 2.1% in the fourth quarter. Principal Financial Group Inc. now owns 1,905,408 shares of the company’s stock valued at $35,135,000 after buying an additional 38,402 shares in the last quarter.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.